Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript September 21, 2023 Valneva SE misses on earnings expectations. Reported EPS is $0.26 EPS, expectations were $0.36. Operator: Good day, and thank you for standing by. Welcome to the Valneva Half Year 2023 Financial Results Call and Webcast. [Operator Instructions] Please note that today’s conference is being […]
Press ReleaseNicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones NCX 470.
Press ReleaseNicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones NCX 470 Mont Blanc Phase 3 clinical
Press ReleaseNicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell DiseaseMarch 2nd, 2022 - release at 7:30 am CET Sophia
Press ReleaseNicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China ZERVIATE (cetirizine ophthalmic solution), 0.24% was non-inferior to comparator